vs

Side-by-side financial comparison of C4 Therapeutics, Inc. (CCCC) and VisionWave Holdings, Inc. (VWAV). Click either name above to swap in a different company.

C4 Therapeutics, Inc. is the larger business by last-quarter revenue ($11.0M vs $10.0M, roughly 1.1× VisionWave Holdings, Inc.). VisionWave Holdings, Inc. runs the higher net margin — -69.4% vs -186.0%, a 116.6% gap on every dollar of revenue.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

CoMix Wave Films, Inc. is a Japanese independent animation film studio and distribution company based in Chiyoda, Tokyo, Japan. The studio is known for its anime feature films, short films, and television commercials, particularly those made by director Makoto Shinkai. It was founded in March 2007 when it split from CoMix Wave Inc., which was initially formed in 1998 from Itochu Corporation, ASATSU, and other companies. On 15 October 2024, Toho announced that they'd acquired 45 shares or 6.0...

CCCC vs VWAV — Head-to-Head

Bigger by revenue
CCCC
CCCC
1.1× larger
CCCC
$11.0M
$10.0M
VWAV
Higher net margin
VWAV
VWAV
116.6% more per $
VWAV
-69.4%
-186.0%
CCCC

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CCCC
CCCC
VWAV
VWAV
Revenue
$11.0M
$10.0M
Net Profit
$-20.5M
$-6.9M
Gross Margin
Operating Margin
-210.1%
-65.7%
Net Margin
-186.0%
-69.4%
Revenue YoY
112.8%
Net Profit YoY
40.7%
-1522.6%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCCC
CCCC
VWAV
VWAV
Q4 25
$11.0M
$10.0M
Q3 25
$11.2M
Q2 25
$6.5M
Q1 25
$7.2M
Q4 24
$5.2M
Q3 24
$15.4M
Q2 24
$12.0M
Q1 24
$3.0M
Net Profit
CCCC
CCCC
VWAV
VWAV
Q4 25
$-20.5M
$-6.9M
Q3 25
$-32.2M
Q2 25
$-26.0M
Q1 25
$-26.3M
Q4 24
$-34.6M
Q3 24
$-24.7M
Q2 24
$-17.7M
Q1 24
$-28.4M
Operating Margin
CCCC
CCCC
VWAV
VWAV
Q4 25
-210.1%
-65.7%
Q3 25
-306.4%
Q2 25
-441.0%
Q1 25
-402.9%
Q4 24
-728.4%
Q3 24
-183.9%
Q2 24
-178.6%
Q1 24
-1060.2%
Net Margin
CCCC
CCCC
VWAV
VWAV
Q4 25
-186.0%
-69.4%
Q3 25
-286.4%
Q2 25
-402.6%
Q1 25
-363.7%
Q4 24
-667.8%
Q3 24
-160.6%
Q2 24
-147.6%
Q1 24
-933.2%
EPS (diluted)
CCCC
CCCC
VWAV
VWAV
Q4 25
$-0.09
Q3 25
$-0.44
Q2 25
$-0.37
Q1 25
$-0.37
Q4 24
$-0.50
Q3 24
$-0.35
Q2 24
$-0.26
Q1 24
$-0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCCC
CCCC
VWAV
VWAV
Cash + ST InvestmentsLiquidity on hand
$74.6M
$15.7K
Total DebtLower is stronger
Stockholders' EquityBook value
$256.6M
$3.1M
Total Assets
$359.1M
$18.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCCC
CCCC
VWAV
VWAV
Q4 25
$74.6M
$15.7K
Q3 25
$58.8M
Q2 25
$78.2M
Q1 25
$51.3M
Q4 24
$55.5M
Q3 24
$59.6M
Q2 24
$73.1M
Q1 24
$89.7M
Stockholders' Equity
CCCC
CCCC
VWAV
VWAV
Q4 25
$256.6M
$3.1M
Q3 25
$154.4M
Q2 25
$174.1M
Q1 25
$195.1M
Q4 24
$216.0M
Q3 24
$242.7M
Q2 24
$247.1M
Q1 24
$258.3M
Total Assets
CCCC
CCCC
VWAV
VWAV
Q4 25
$359.1M
$18.4M
Q3 25
$265.5M
Q2 25
$296.5M
Q1 25
$319.5M
Q4 24
$349.6M
Q3 24
$376.1M
Q2 24
$381.1M
Q1 24
$398.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCCC
CCCC
VWAV
VWAV
Operating Cash FlowLast quarter
$-22.1M
$-5.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCCC
CCCC
VWAV
VWAV
Q4 25
$-22.1M
$-5.4M
Q3 25
$-31.2M
Q2 25
$-12.1M
Q1 25
$-33.3M
Q4 24
$-17.9M
Q3 24
$-24.1M
Q2 24
$-5.0M
Q1 24
$-18.1M
Free Cash Flow
CCCC
CCCC
VWAV
VWAV
Q4 25
Q3 25
$-31.6M
Q2 25
Q1 25
Q4 24
$-17.9M
Q3 24
$-24.1M
Q2 24
$-5.2M
Q1 24
FCF Margin
CCCC
CCCC
VWAV
VWAV
Q4 25
Q3 25
-281.5%
Q2 25
Q1 25
Q4 24
-346.5%
Q3 24
-157.2%
Q2 24
-43.1%
Q1 24
Capex Intensity
CCCC
CCCC
VWAV
VWAV
Q4 25
Q3 25
3.7%
Q2 25
Q1 25
Q4 24
0.1%
Q3 24
0.1%
Q2 24
1.6%
Q1 24
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons